{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-051917","form_type":"8-K","ticker":"STRO","cik":"0001382101","company_name":"SUTRO BIOPHARMA, INC.","filed_at":"2023-10-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.808237+00:00","generated_at":"2026-06-10T04:37:59.334202+00:00","sec_items":["1.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Sutro Biopharma and Vaxcyte finalize agreement triggering $5M payment; license amended","bullets":["Vaxcyte agrees to pay Sutro $5.0M upon mutual agreement on Form Definitive Agreement, reached Sept 28, 2023.","Amendment No. 3 modifies royalty reduction provisions, IP ownership, prosecution, and financial reporting terms.","Vaxcyte gains rights to independently source cell-free extract from CMOs and option to internally manufacture extract.","Amendment effective immediately; negotiated under December 2022 letter agreement between the companies."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-051917","json":"https://secwatch.observer/filing/0000950170-23-051917.json","markdown":"https://secwatch.observer/filing/0000950170-23-051917.md","text":"https://secwatch.observer/filing/0000950170-23-051917.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1382101/000095017023051917/0000950170-23-051917-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1382101/000095017023051917/stro-20230928.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T04:37:59.334202+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}